Two decades ago, treatment for active psoriatic arthritis (PsA) focused mainly on controlling pain and slowing joint damage. Today, innovation has completely changed the treatment landscape.
Doctors now have access to targeted biologics and advanced oral medicines that suppress specific inflammatory pathways instead of broadly weakening the immune system. These therapies not only reduce joint swelling but also improve skin symptoms, physical function, and long-term quality of life.
According to the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), nearly 30% of people living with psoriasis eventually develop psoriatic arthritis, making early diagnosis and effective treatment essential.
The Disease Burden Continues to Rise
Psoriatic arthritis is no longer considered a rare disease.
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 67.1 million U.S. adults have diagnosed arthritis. Around 1 million Americans are living with psoriatic arthritis, representing about 1.4% of all diagnosed arthritis cases and 0.3% of the total adult U.S. population.
Government health data also show that 21.3% of U.S. adults had diagnosed arthritis in 2024, highlighting the growing burden of musculoskeletal diseases on healthcare systems.
Without treatment, persistent inflammation can permanently damage joints, reduce mobility, and increase healthcare costs through disability, surgery, and long-term rehabilitation.
The Pharmaceutical Companies Leading Innovation
AbbVie – Skyrizi Is One of the Fastest-Growing Immunology Brands
AbbVie has become one of the biggest innovators in autoimmune diseases through Skyrizi (risankizumab).
The medicine selectively blocks interleukin-23 (IL-23), one of the major inflammatory proteins responsible for psoriasis and psoriatic arthritis.
AbbVie reported approximately US$11.7 billion in Skyrizi sales during 2024, representing one of the fastest revenue growth rates among immunology medicines.
Clinical trials have demonstrated significant improvements in joint tenderness, swollen joint counts, skin clearance, physical function, and minimal disease activity.
Looking for answers to your specific business questions? Our experts provide FREE customized sample reports: https://www.towardshealthcare.com/download-sample/6427
Johnson & Johnson Continues Expanding Its Leadership
Johnson & Johnson has remained a global leader through two blockbuster brands.
Stelara (ustekinumab) pioneered IL-12/23 inhibition and became one of the world’s highest-selling biologics.
The company generated over US$10 billion in global Stelara sales in 2024, despite increasing biosimilar competition.
Its newer medicine, Tremfya (guselkumab), selectively targets IL-23 and has shown strong clinical outcomes for both joint inflammation and skin disease while requiring relatively infrequent dosing.
Novartis Revolutionized Treatment with Cosentyx
When Cosentyx (secukinumab) entered the market, it became the first IL-17A inhibitor approved for psoriatic arthritis.
Rather than targeting older inflammatory pathways, Cosentyx blocks IL-17A, a cytokine directly involved in joint and skin inflammation.
Novartis generated approximately US$6 billion in Cosentyx sales during 2024, reflecting its widespread global adoption.
Long-term extension studies continue to demonstrate sustained improvements in disease activity for many patients receiving continuous therapy.
Amgen Offers an Effective Oral Alternative
Not every patient is ready for injections.
Otezla (apremilast), developed originally by Celgene and now marketed by Amgen, remains one of the leading oral therapies for active psoriatic arthritis.
By inhibiting phosphodiesterase-4 (PDE4), Otezla reduces inflammatory signaling without requiring biologic injections.
The product continues generating more than US$2 billion in annual global revenue, making it one of the most successful oral immunology medicines worldwide.
Bristol Myers Squibb Introduces a New Treatment Class
Innovation is also moving beyond biologics.
Sotyktu (deucravacitinib) became the first selective TYK2 inhibitor, opening an entirely new class of targeted oral immunology medicines.
Researchers believe TYK2 inhibition may provide strong disease control while minimizing unwanted immune suppression compared with older oral therapies.
Multiple clinical development programs continue evaluating its broader role across immune-mediated inflammatory diseases.
Government Agencies Are Accelerating Innovation
The U.S. Food and Drug Administration (FDA) continues approving innovative biologics, targeted therapies, and interchangeable biosimilars to improve patient access and increase treatment competition.
According to FDA drug approval reports, several biosimilars for leading inflammatory disease medicines—including Eticovo, Hadlima, and Hyrimoz—received expanded approvals, increasing treatment affordability for patients with immune-mediated diseases.
Government investment in clinical research has also accelerated the development of highly targeted therapies designed to improve efficacy while reducing long-term safety concerns.
Innovation Leaders at a Glance
| Drug Brand | Company | Target | First Major Innovation | Approx. 2024 Sales |
|---|---|---|---|---|
| Skyrizi | AbbVie | IL-23 | Selective IL-23 inhibition | US$11.7 Billion |
| Stelara | Johnson & Johnson | IL-12/23 | First major IL-12/23 biologic | >US$10 Billion |
| Cosentyx | Novartis | IL-17A | First IL-17A biologic | ~US$6 Billion |
| Tremfya | Johnson & Johnson | IL-23 | High-selectivity IL-23 inhibitor | Multi-billion-dollar global brand |
| Otezla | Amgen | PDE4 | Leading oral targeted therapy | >US$2 Billion |
| Sotyktu | Bristol Myers Squibb | TYK2 | First selective TYK2 inhibitor | Rapidly expanding global launch |
The Next Chapter of Psoriatic Arthritis Care
Competition among pharmaceutical companies is no longer focused only on launching new drugs.
Manufacturers are investing billions of dollars in biomarker research, precision medicine, combination therapies, artificial intelligence–assisted drug discovery, and personalized treatment strategies that can predict which patients will respond best.
For patients living with active psoriatic arthritis, this innovation race is translating into earlier diagnosis, better disease control, fewer hospital visits, improved mobility, and a greater chance of maintaining normal daily activities.
As governments continue supporting faster regulatory pathways and pharmaceutical companies expand investment in immunology research, the future of psoriatic arthritis treatment is expected to become even more targeted, effective, and patient-centered.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium